Supplement |

Action on neovascular age-related macular degeneration (nAMD): 2018 update

An expert clinical advisory group named Action on nAMD met on 16 March 2018 in Birmingham, UK, to explore and discuss multidisciplinary practice initiatives and service developments in the management of nAMD. Medical writing support was provided by Rod McNeil from Rod McNeil Associates and was funded by Bayer.

This publication and the expert roundtable meeting on which the paper is based were sponsored by Bayer plc. Bayer checked that the content was factually accurate, balanced and compliant with the Association of the British Pharmaceutical Industry Code of Practice. The views expressed are those of the author(s) and are not necessarily those of Bayer or the NHS.

Prescribing information for Eylea® (aflibercept solution for injection) can be found at the end of the article.

Item Code: PP-EYL-GB-0246. Date of Preparation: May 2019.

Content